Shaily Engineering Plastics FY26: Rs 3 Dividend, Rs 500 Cr

Board meeting: what the company approved on May 19, 2026

Shaily Engineering Plastics said its Board of Directors met on May 19, 2026, to approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The meeting had been pre-announced to stock exchanges under Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Alongside the results, the board considered shareholder-linked items, including a final dividend recommendation for FY26. It also took up a capital-raising proposal framed as an enabling resolution, which allows the company to raise funds in one or more tranches, subject to required approvals.

The disclosures also referenced a key business development: the Healthcare segment secured an order worth Rs 423 crore for pen injectors. That order size, along with the FY26 profitability numbers, put the board’s capital allocation decisions in focus.

Dividend: Rs 3 per share recommended for FY26

The board recommended a final dividend of Rs 3 per equity share of face value Rs 2 each, described as 150% for the year ended March 31, 2026. The company stated that the dividend remains subject to shareholder approval at the forthcoming Annual General Meeting.

The announcement gives investors a clear dividend number ahead of the AGM, but it does not include a record date or payment date in the provided information. Any next steps on timelines would typically follow in subsequent corporate actions after shareholder approval.

Fund-raise enabling resolution: up to Rs 500 crore

A central item at the meeting was an enabling resolution to raise funds of up to Rs 500 crore. The company indicated the fund-raise could be done in one or more tranches through permissible modes such as private placement, preferential issue, or rights issue.

The disclosure describes the resolution as “enabling”, meaning it authorises the company to proceed when needed rather than confirming immediate issuance. It also noted the proposal would remain subject to necessary regulatory and statutory approvals, and shareholder approval where applicable.

Healthcare order: Rs 423 crore for pen injectors

Shaily Engineering Plastics’ Healthcare segment secured an order worth Rs 423 crore for pen injectors, as stated in the provided information. While the disclosure does not specify delivery schedules, customer name, or revenue recognition timelines, the size of the order is material when compared with quarterly revenue levels.

For investors tracking the company’s product mix and end-market exposure, the order reinforces Healthcare as a meaningful contributor to the company’s growth narrative, particularly as it coincides with strong FY26 profit growth.

FY26 financial snapshot: revenue, income, and profits

The company disclosed audited performance figures for both standalone and consolidated results. To make the numbers comparable, all revenue and income figures below are presented in Rs crore (converted from Rs lakh).

Standalone results show FY26 revenue from operations of Rs 990.67 crore, up 25.91% year-on-year versus FY25. FY26 net profit after tax (PAT) stood at Rs 169.91 crore, up 82.47% year-on-year.

On a quarterly basis, standalone Q4FY26 revenue from operations was Rs 236.82 crore, down 5.46% quarter-on-quarter but up 8.72% year-on-year. Standalone Q4FY26 PAT was Rs 40.16 crore, up 7.43% quarter-on-quarter and up 40.46% year-on-year.

Consolidated results show FY26 revenue from operations of Rs 921.20 crore, up 24.80% year-on-year. FY26 profit before tax (PBT) was Rs 211.86 crore, up 123.81% year-on-year. For Q4FY26, consolidated revenue from operations was Rs 224.07 crore, down 5.23% quarter-on-quarter and up 10.22% year-on-year.

Key audited financials (as disclosed)

Other board decisions: auditors, ESOPs, and subsidiary plan

Beyond results, dividend, and fund-raising, the board approved audit-related appointments for FY2026-27. It appointed M/s Jain & Hindocha, Chartered Accountants, as Internal Auditor, and M/s YS Thakar & Co, Cost Accountants, as Cost Auditor.

Separately, the company said its Nomination and Remuneration Committee approved the grant of 3,000 stock options under ESOP 2019 on May 19, 2026. The disclosure does not specify exercise price, vesting schedule, or grant date mechanics beyond the approval.

The board also decided not to proceed with incorporating a proposed domestic wholly-owned subsidiary, stating it was no longer required.

Trading window closure under SEBI regulations

Shaily Engineering Plastics stated that its trading window remained closed from April 1, 2026, through May 21, 2026. The company cited compliance with SEBI insider trading regulations for the closure period.

For market participants, the disclosure clarifies the compliance window around the audited results process and board decision-making timeline.

Stock price and near-term market context

The provided information includes multiple market price points. One data point shows the stock last traded at Rs 3,061.80, with a move of -153.70 (-5.33%). Another data point states that as of June 8, 2026 at 11:52 AM IST, Shaily Engg Plastics share price was Rs 3,077.10, up 0.47% compared with the previous closing price of Rs 3,067.4.

These figures indicate that price action around the period was mixed across different snapshots, while the corporate updates included a dividend recommendation and a sizeable enabling fund-raise.

Summary table: key corporate actions announced

Why the FY26 outcome matters for investors

The FY26 numbers highlight a sharp year-on-year rise in profitability, with standalone PAT growth of 82.47% and higher EPS (standalone basic EPS of Rs 36.97 versus Rs 20.29 in FY25, as disclosed). At the same time, the board’s decision to seek an enabling fund-raise of up to Rs 500 crore indicates the company wants flexibility to access capital through equity or equity-linked routes.

The combination of a final dividend recommendation and a potential equity-linked fund raise often draws investor attention because it reflects how management is balancing shareholder returns with growth funding. In parallel, the Rs 423 crore Healthcare order provides a business data point that can be tracked in future quarters for execution, subject to further company disclosures.

Conclusion

Shaily Engineering Plastics’ May 19, 2026 board meeting delivered three key outcomes: FY26 audited results approval, a final dividend recommendation of Rs 3 per share, and an enabling resolution to raise up to Rs 500 crore. The company also referenced a Rs 423 crore pen injector order in its Healthcare segment and made routine governance decisions including auditor appointments and ESOP grants.

The next confirmed step in the dividend process is shareholder approval at the forthcoming AGM, while any fund-raise would depend on subsequent approvals and specific issuance announcements.